95 related articles for article (PubMed ID: 18508797)
1. Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia.
Jönsson S; Olsson B; Ohlsson C; Lorentzon M; Mellström D; Wadenvik H
Haematologica; 2008 Jul; 93(7):1101-3. PubMed ID: 18508797
[No Abstract] [Full Text] [Related]
2. Imatinib-induced cytogenetic remission in chronic eosinophilic leukaemia.
Willson A; Cannell P; Joske D; Augustson B
Intern Med J; 2006 Aug; 36(8):537-8. PubMed ID: 16866664
[No Abstract] [Full Text] [Related]
3. Different kinetic patterns of BCR-ABL transcript levels in imatinib-treated chronic myeloid leukemia patients after achieving complete cytogenetic response.
Qin YZ; Liu YR; Zhu HH; Li JL; Ruan GR; Zhang Y; Jiang Q; Jiang H; Li LD; Chang Y; Huang XJ; Chen SS
Int J Lab Hematol; 2008 Aug; 30(4):317-23. PubMed ID: 18665830
[TBL] [Abstract][Full Text] [Related]
4. Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate.
Hwang YY; Tse E; So JC; Wan TS; Kwong YL
Am J Hematol; 2009 May; 84(5):302-5. PubMed ID: 19338042
[No Abstract] [Full Text] [Related]
5. Imatinib treatment of seropositive arthritis in a young woman with chronic myeloid leukemia.
Ames PR; Aye WW; Beatty C; O'Reilly D
J Rheumatol; 2008 Aug; 35(8):1682. PubMed ID: 18671330
[No Abstract] [Full Text] [Related]
6. Achievement of complete molecular responses in late chronic phase chronic myeloid leukaemia patients treated with pulsed imatinib while in minimal residual disease.
Breccia M; Cannella L; Stefanizzi C; Santopietro M; De Cuia R; Diverio D; Alimena G
Leuk Res; 2009 May; 33(5):645-8. PubMed ID: 19062090
[TBL] [Abstract][Full Text] [Related]
7. Persistence of molecular remission throughout pregnancy in CML after imatinib.
Sorà F; De Matteis S; Bajer J; D'alò F; Leone G; Sica S
Leuk Res; 2009 Jun; 33(6):e6-7. PubMed ID: 18937976
[No Abstract] [Full Text] [Related]
8. Brain natriuretic peptide level as marker of cardiac function in imatinib--treated chronic myeloid leukemia patients: no evidence of cardiotoxicity of imatinib therapy.
Tiribelli M; Colatutto A; Marin L; Barbina G; Qualizza U; Damiani D; Toffoletti E; Medeot M; Candoni A; Tonutti E; Sala P; Fanin R
Am J Hematol; 2008 Jun; 83(6):517-8. PubMed ID: 18306359
[No Abstract] [Full Text] [Related]
9. Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia.
Nagasaki Y; Miyamoto T; Henzan H; Nagafuji K; Harada M; Akashi K
J Rheumatol; 2009 Jun; 36(6):1349-51. PubMed ID: 19509096
[No Abstract] [Full Text] [Related]
10. Successful imatinib mesylate therapy for acquired von Willebrand syndrome in chronic myelogenous leukemia.
Uchiyama M; Ikeda T
Leuk Res; 2009 Dec; 33(12):1723-4. PubMed ID: 19580999
[No Abstract] [Full Text] [Related]
11. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
Breccia M; Alimena G
Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
[TBL] [Abstract][Full Text] [Related]
12. Molecular response to imatinib in patient with Ph negative p190 BCR-ABL transcript positive chronic myeloid leukemia with cyclic leukocytosis.
Radojkovic M; Ristic S; Pavlovic S; Colovic M
Leuk Res; 2009 Jun; 33(6):e10-2. PubMed ID: 19091403
[TBL] [Abstract][Full Text] [Related]
13. Compliance with taking imatinib mesylate in patients with chronic myeloid leukemia in the chronic phase.
Kiguchi T; Tauchi T; Ito Y; Miyazawa K; Kimura Y; Ohyashiki K
Leuk Res; 2009 Mar; 33(3):506-8. PubMed ID: 18533259
[No Abstract] [Full Text] [Related]
14. Double Philadelphia-chromosome: a resistance factor on the imatinib mesylate therapy for chronic myeloid leukemia.
Otero L; Ornellas MH; Dobbin J; de Souza Fernandez T
Int J Lab Hematol; 2008 Aug; 30(4):346-8. PubMed ID: 18665834
[No Abstract] [Full Text] [Related]
15. Management of conjunctival chemosis secondary to imatinib treatment for chronic myelogenous leukemia.
Jin J; Chen H; Cao L
Leuk Res; 2009 Jun; 33(6):e18-9. PubMed ID: 19108890
[No Abstract] [Full Text] [Related]
16. Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
Vernon MR; Pearson L; Atallah E
J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496
[No Abstract] [Full Text] [Related]
17. Imatinib dose escalation to achieve molecular responses in patients with chronic myeloid leukemia in late chronic phase.
Stagno F; Vigneri P; Del Fabro V; Stella S; Massimino M; Berretta S; Messina A; Di Raimondo F
Leuk Res; 2009 Jun; 33(6):e17. PubMed ID: 19036439
[No Abstract] [Full Text] [Related]
18. Development of hypogammaglobulinemia in patients treated with imatinib for chronic myeloid leukemia or gastrointestinal stromal tumor.
Santachiara R; Maffei R; Martinelli S; Arcari A; Piacentini F; Trabacchi E; Alfieri P; Ferrari A; Leonardi G; Luppi G; Longo G; Vallisa D; Marasca R; Torelli G
Haematologica; 2008 Aug; 93(8):1252-5. PubMed ID: 18519520
[TBL] [Abstract][Full Text] [Related]
19. Interferon-alpha is able to maintain complete molecular remission induced by imatinib after its discontinuation.
Carella AM
Leukemia; 2008 May; 22(5):1090-1. PubMed ID: 18385749
[No Abstract] [Full Text] [Related]
20. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
